Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Theravance Biopharma (TBPH) EBITDA Margin (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed EBITDA Margin for 13 consecutive years, with 18.29% as the latest value for Q3 2025.

  • On a quarterly basis, EBITDA Margin rose 8254.0% to 18.29% in Q3 2025 year-over-year; TTM through Sep 2025 was 44.44%, a 12120.0% increase, with the full-year FY2024 number at 14.29%, down 201084.0% from a year prior.
  • EBITDA Margin was 18.29% for Q3 2025 at Theravance Biopharma, down from 209.3% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 7361.3% in Q3 2022 to a low of 1038.96% in Q1 2022.
  • A 5-year average of 250.43% and a median of 88.29% in 2025 define the central range for EBITDA Margin.
  • Peak YoY movement for EBITDA Margin: soared 762886bps in 2022, then tumbled -741794bps in 2023.
  • Theravance Biopharma's EBITDA Margin stood at 267.56% in 2021, then soared by 56bps to 119.0% in 2022, then skyrocketed by 52bps to 56.64% in 2023, then grew by 13bps to 49.06% in 2024, then skyrocketed by 137bps to 18.29% in 2025.
  • Per Business Quant, the three most recent readings for TBPH's EBITDA Margin are 18.29% (Q3 2025), 209.3% (Q2 2025), and 88.29% (Q1 2025).